Patients with fibromyalgia have access to a limited number of therapeutic options. One of 3 drugs approved for patients with fibromyalgia, pregabalin is an anticonvulsant and α-2-Δ subunit receptor ligand that has shown clinically meaningful benefits across multiple fibromyalgia symptom domains.
Although fibromyalgia (FM) is better understood and recognized today than it was 25 years ago when FM classification criteria (ie, history of widespread pain, and pain on palpation of ≥11 of 18 specific sites) were first published, researchers still have an incomplete understanding of FM's mechanisms and predictors.
Fibromyalgia flares are associated with intense pain, flulike aches and exhaustion, and other phenomena such as “brain fog,” as confirmed by the first-ever qualitative analysis of these periods of symptom exacerbation. Furthermore, according to the 44 people who responded to the investigators’ survey, the patients tried many coping techniques, from medications to massage and from meditation to humor.
Review of Appeals of Fibromyalgia-Related Workplace Injury Compensation Cases Sheds Light on the Medicolegal Aspects of the Disease
By Rosemary Frei, MSc Winnipeg, Manitoba—There are lessons for rheumatologists and for family physicians in how courts adjudicate cases of fibromyalgia that were alleged to have been caused by or exacerbated by workplace injury, according to a new study presented at the Canadian Pain Society’s 2013 annual meeting and was published simultaneously (Fitzcharles MA, et al. J Rheumatol. 2013;40:323-328).
By Phoebe Starr The way patients with fibromyalgia experience pain may be a result of abnormal pain signal processing associated with reduced opioid receptor binding, according to a study presented during the 2012 meeting of the American College of Rheumatology.
First Japanese clinical trial for this condition By Charles Bankhead Patients with fibromyalgia had significant improvement in pain, sleep, and quality-of-life measures when treated with pregabalin (Lyrica) versus placebo, according to the results of the first clinical trial of this condition in Japan (Ohta H, et al. Arthritis Res Ther. 2012;14:R217 [Epub ahead of print]). Significant pain relief occurred within the first week of treatment with pregabalin and persisted over the 15-week duration of the trial. Significantly more patients reported being “very much improved” or “much improved” with pregabalin than with placebo (P = .078).
Page 1 of 2
Results 1 - 10 of 14
Results 1 - 10 of 14